Financial Results
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fischer Medical Ventures reported audited results for FY26 ended March 2026. Standalone revenue grew 233% to Rs 1,739.18 lakhs from Rs 521.97 lakhs, but the company swung to a net loss of Rs 1,042.29 lakhs from a profit of Rs 66.32 lakhs in FY25. Consolidated revenue declined marginally to Rs 9,773.04 lakhs from Rs 10,109.52 lakhs, with consolidated net loss at Rs 709.78 lakhs versus profit of Rs 1,923.48 lakhs in FY25. Despite the loss, the board recommended a final dividend of Rs 0.05 per share. Statutory auditors issued an unmodified opinion on both standalone and consolidated financials.
The stock may face pressure as the company reported significant losses in FY26 despite standalone revenue growth. The sharp turnaround from profit to loss raises concerns about operational efficiency and cost management, particularly given high finance costs of Rs 465.23 lakhs in standalone operations.